Stanley Fahn lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered

Movement Disorders

Volumn 21, Issue 12, 2006, Pages 2042-2051

  Braak, Heiko ^a   Bohl, Jürgen R ^b   Müller, Christian M ^a   Rüb, Udo ^a   de Vos, Rob A I ^c   Del Tredici, Kelly ^a  

^a GOETHE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Laboratorium Pathologie Oost Nederland   (Netherlands)

Author keywords

synuclein; Aging; Lewy bodies neurites; Pathoarchitectonics; Sporadic Parkinson's disease; Staging

Indexed keywords

SYNUCLEIN;

AGED; AUTONOMIC NERVOUS SYSTEM; AUTOPSY; BRAIN REGION; CELL INCLUSION; CELL TYPE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOREBRAIN; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEWY BODY; LIMBIC SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDULLA OBLONGATA; MOTOR SYSTEM; NEOCORTEX; NERVE CELL LESION; NEURITE; OLFACTORY SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; TEGMENTUM;

ANIMALS; DISEASE PROGRESSION; HUMANS; INCLUSION BODIES; PARKINSON DISEASE;

EID: 33846419768     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21065     Document Type: Review

References (110)

1. Lewy FH. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowski M, editor. Handbuch der Neurologie, Bd. 3, Berlin: Springer; 1912. p 920-933.
2. den Hartog WA, Jager W, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960;23:283-290.
3. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991;14: 153-197.
4. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003;18(Suppl. 6):2-12.
5. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution - a pilot study. Acta Neuropathol 2003;106:191-201.
6. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990; 79:581-583.
7. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 1993;60:609-612.
8. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997; 38(Suppl. 2):2-7.
9. Braak H, de Vos RAI, Jansen ENH, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog Brain Res 117;1998:267-285.
10. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
11. Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's disease and incidental Lewy body diseases. Neurology 1999;52:1269-1271.
12. Jellinger KA, Mizuno Y. Parkinson's disease. In: Dickson DW, editor. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropathologica Press; 2003. p 159-187.
13. Trojanowsi JQ, Lee VM-Y. Meeting summary - cell biology of Parkinson's disease and related neurodegenerative disorders. Sci Aging Knowledge Environ 2003;32:1-9.
14. Eriksen JL, Zbigniew W, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005;62:353-357.
15. Hardy J, Lees AJ. Parkinson's disease: a broken nosology. Mov Disord 2005;20(Suppl. 12):S2-S4.
16. Lowe J. Lewy bodies. In: Calne DP, editor. Neurodegenerative Diseases. Philadelphia: WB Saunders; 1994. p 51-69.
17. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272.
18. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997;388: 839-840.
19. Wakabayashi K, Hayashi S, Kakita A, et al. Accumulation of α-synuclein/ NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 1998; 96:445-452.
20. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 2000;920:16-27.
21. Takahashi H, Wakabayashi K. The cellular pathology of Parkinson's disease. Neuropathology 2001;21:315-322.
22. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003;62:1241-1253.
23. Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated α-synuclein in aging human brain. J Neuropathol Exp Neurol 2003;62:644-654.
24. Mikolaenko I, Pletnikova O, Kawas CH, et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 2005;64:156-162.
25. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
26. Del Tredici K, Braak H. Idiopathic Parkinson's disease: staging an α- synucleinopathy with a predictable pathoanatomy. In: Kahle P, Haass C, editors. Molecular Mechanisms in Parkinson's Disease. Georgetown, TX: Landes Bioscience; 2004. p 1-32.
27. Braak H, Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2004;25:19-23.
28. van der Knaap MS, Valk J, Bakker CJ, et al. Myelination as an expression of the functional maturity of the brain. Dev Med Child Neurol 1991;33:849-857.
29. Nieuwenhuys R. Structure and organization of fibre systems. In: Nieuwenhuys R, Ten Dorkelaar JH, Nicholson C, editors. The Nervous System of Vertebrates. Vol. 1. Berlin: Springer; 1999. p 113-157.
30. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-366.
31. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-144.
32. Sohal RS. Oxidative stress hypothesis of aging. Free Radic Biol Med 2002;33:573-574.
33. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl. 3):26-38.
34. Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 2005;20:271-282.
35. Kapfhammer JP, Schwab ME. Inverse patterns of myelination and GAP-43 expression in the adult CNS: neurite growth inhibitors as regulators of neuronal plasticity. J Comp Neurol 1994; 340:194-206.
36. Del Tredici K, Rüb U, de Vos RAI, Bohl JRE, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-426.
37. Thal DR, Del Tredici K, Braak H. Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ 2004;23: 1-13.
38. Forno LS. Concentric hyaline intraneuronal inclusions of Lewy body type in the brain of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 1969;17:557-575.
39. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;55:138-142.
40. Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological aging. Neurobiol Aging 1992;17:365-371.
41. Braak H, Braak E, Yilmazer D, Schultz C, Bohl J. Age-related changes of the human cerebral cortex. In: Cruz-Sanchez FF, Ravid R, Cuzner ML, editors. Neuropathological Diagnostic Criteria for Brain Banking. Biomedical Health Research. Vol. 10. Amsterdam: IOS Press; 1995. p 14-19.
42. Dickson DW. Aging in the central nervous system. In: Markesbery WR, editor. Neuropathology of Dementing Disorders. New York: Arnold; 1998. p 56-88.
43. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-316.
44. Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson's disease? Neurology 1991; 41(Suppl. 2):8-13.
45. Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord 1993; 8:271-277.
46. Wolters EC, Francot C, Bergmans P, et al. Preclinical (premotor) Parkinson's disease. J Neurol 2000;247(Suppl. 2):103-109.
47. Jankovic J. Progression of Parkinson's disease. Are we making progress in charting the course? Arch Neurol 2005;62:351-352.
48. Morrish PK, Rakashi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with (18F)dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
49. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000; 247(Suppl. 2):11-18.
50. Lees AJ. Early diagnosis of Parkinson's disease. Br J Hosp Med 1981;26:511-512, 517-518.
51. Przuntek H. Early diagnosis in Parkinson's disease. J Neural Transm 1992;38(Suppl.):105-114.
52. Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. Neurology 1983;33:943-946.
53. Berendse HW, Booij J, Francot CM, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50: 34-41.
54. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001;16:41-46.
55. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-181.
56. Vaserman-Lehuede N, Verin M. Shoulder pain in patients with Parkinson's disease. Rev Rhum Engl Ed 1999;66:220-223.
57. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996;46:388-393.
58. Stiasny-Kolster K, Doeff Y, Möller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005;128:126-137.
59. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462.
60. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-116.
61. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-589.
62. 23I-metaiodobenzylguanidine myorcardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-194.
63. Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003;18:890-897.
64. Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm. 2004;111:201-216.
65. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - a new disease? Clin Neuropathol 1984;3:185-192.
66. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990; 237:197-204.
67. Kosaka K, Iseki E. Diffuse Lewy body disease. In: Perry RH, McKeith IG, Perry EK, editors. Dementia With Lewy Bodies. Clinical, Pathological, and Treatment Issues. Cambridge, UK: Cambridge University Press; 1996. p 238-247.
68. Kosaka K, Iseki E, Odawara T, Yamamoto T. Cerebral type of Lewy body disease. Neuropathology 1996;16:32-35.
69. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium of DLB international workshop. Neurology 1996;47:1113-1124.
70. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
71. Marui W, Iseki E, Nakai T, et al. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 2002;195:153-159.
72. Hegeman Richard I, Papka M, Rubio A, Kurlan R. Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov Disord 2002;17:1161-1165.
73. Braak H, Rüb U, Jansen Steur ENH, Del Tredici K, de Vos RAI. Cognitive status correlates with neuropathological stage in Parkinson disease. Neurology 2005;64:1404-1410.
74. Rachakonda V, Pan TH, Le WD. Biomarkers of neurodegenerative disorders: how good are they? Cell Res 2004;14:349-360.
75. Eadie MJ. The pathology of certain medullary nuclei in parkinsonism. Brain 1963;86:781-795.
76. Daniel SE, Hawkes CH. Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. Lancet 1992;340:186.
77. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995;10:283-287.
78. Mesholam RL, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease. A meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol 1998; 55:84-90.
79. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson's disease a primary olfactory disorder? Q J Med 1999;92:473-480.
80. Doty RL. Olfaction. Annu Rev Psychol 2001;52:423-452.
81. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord 2003;18:364-372.
82. Saper CB, Sorrentino DM, German DC, de Lacalle S. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. Ann Neurol 1991;29:577-594.
83. Braak H, Rüb U, Sandmann-Keil D, et al. Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol 2000;99: 489-495.
84. Bohus B, Koolhaas JM, Luiten PGM, Korte SM, Roozendaal B, Wiersma A. The neurobiology of the central nucleus of the amygdala in relation to neuroendocrine and autonomic outflow. Prog Brain Res 1996;107:447-460.
85. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999;22:273-280.
86. Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson's disease. Brain 2000;123:1767-1783.
87. Braak H, Braak E. Nuclear configuration and neuronal types of the nucleus niger in the brain of the human adult. Hum Neurobiol 1986;5:71-82.
88. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54: 388-396.
89. Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol 1994;88:493-500.
90. Braak H. Architectonics of the Human Telencephalic Cortex. Berlin: Springer; 1980.
91. Braak H, Braak E. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res 1992;15:6-31.
92. Dickson DW, Schmidt ML, Lee VMY, Zbao ML, Yen SH, Trojanowski JQ. Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol 1994; 87:269-276.
93. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112.
94. Calne DB, Mizuno Y. The neuromythology of Parkinson's disease. Parkinsonism Relat Disord 2004;10:319-322.
95. Lavadan C. The synuclein family. Genome Res 1998;8:871-880.
96. Takahashi H, Wakabayashi K. Controversy: is Parkinson's disease a single disease entity? Yes. Parkinsonism Relat Disord 2005;10:319-322.
97. Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I. α-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005;57:82-91.
98. Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004;3:496-503.
99. Trojanowski JQ, Goedert M, Iwatsubo, T, Lee VM. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ 1998; 5:832-837.
100. Ciechanover A, Brundin P. The ubiquitin proteosome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003;40:427-446.
101. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. Caught in the act: α-Synuclein is the culprit in Parkinson's disease. Neuron 2003;40:453-456.
102. Volles MJ, Lansbury PT Jr. Zeroing in on the pathogenic form of α-Synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003;42:7871-7878.
103. Parkkinen L, Soininen H, Laakso M, Alafazoff I. Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer's disease. J Neuropathol Exp Neurol 2003;62:363-367.
104. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004;111:1219-1235.
105. Saito Y, Ruberu NN, Sawabe M, et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 2004;63:742-749.
106. Neumann M, Müller V, Kretschmar HA, Haass C, Kahle PJ. Regional distribution of proteinase-K a-synuclein correlates with Lewy body disease stage. Neuropathol Exp Neurol 2004;63:1225-1235.
107. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol 2000;10:378-384.
108. Geddes JW. α-Synuclein: a potent inducer of tau pathology. Exp Neurol 2005;192:244-250.
109. Aarsland D, Ballard CG, Halliday GH. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004;17:137-145.
110. Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. TINS 2004;27: 129-134.